These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy of Neurology (AAN) Annual Meeting, providing insight into its potential to ...

This CME program is designed to enhance neurologists' understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in ...

In addition, Amgen has unveiled results from the Phase 3 MINT trial of its drug UPLIZNA, showing sustained efficacy in treating generalized myasthenia gravis, with no new safety signals identified.

Patients were eligible for the study if they had Myasthenia Gravis Foundation of America classification ... executive vice president of Research and Development at Amgen. “These findings reinforce ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.